FIELD: medicine, endocrinology. SUBSTANCE: invention relates to treatment of diabetes mellitus and diabetes-associated complications. Invention proposes to administrate preparation among the group involving enhancers for sensitivity to insulin but excluding troglitazone in combination with preparation taken among the group of involving enhancers of insulin secretion and taken also among inhibitors of alpha-glycosidase, inhibitors of alpha-reductase, biguanides, statin compounds, inhibitors of squalene, fibrate compounds, enhancers of LDL (low density lipoproteins) catabolism and inhibitors of ACF (augiotensinconversional ferment). Combinations of these preparations are administrated as a mixture also. Indicated combinations, except for hypoglycemic effect, provide reducing weight, blood plasma triglycerides level, unexpectedly high activity with respect to reducing blood glucose level being in retention of dose of insulin sensitivity enhancer. EFFECT: enhanced and valuable properties of enhancers. 12 cl, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREVENTION AND TREATMENT AND RELATED COMPLICATION | 1996 |
|
RU2327455C2 |
METHODS FOR PROPHYLAXIS AND TREATMENT, APPLICATION OF AGENT TO ENHANCE INSULIN SUSCEPTIBILITY | 2003 |
|
RU2286148C2 |
PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2198682C2 |
PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2323004C2 |
PANCREATIC DIABETES DRUG | 2004 |
|
RU2358738C2 |
THERAPEUTIC ANTIDIABETIC AGENT | 2006 |
|
RU2438671C2 |
O-ARYLGLUCOSIDE INHIBITORS OF SGLT2 AND METHOD FOR THEIR USING | 2001 |
|
RU2269540C2 |
PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DIABETES AND RELATED METABOLIC DISEASES | 2021 |
|
RU2809286C1 |
PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2532330C2 |
COMBINATED INHIBITORS OF FBP-ASE AND ANTIDIABETIC AGENTS FOR DIABETES TREATMENT | 2001 |
|
RU2328308C2 |
Authors
Dates
2004-02-20—Published
1996-06-19—Filed